Lupin gets FDA nod to launch heart drug in the US

Pharma manufacturer Lupin said it received approval to launch the generic version of US World Meds’ Corgard heart drug.

Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately USD 109.8 million in the US, the Indian drugmaker said.

Lupin’s Nadolol Tablets are the AB rated generic equivalent of US World Meds, meaning that they can be substituted by the pharmacist for the branded version.

The drug is indicated for management of patients with angina pectoris and for the treatment of hypertension.

Angina refers to chest pain or discomfort due to coronary heart disease. It occurs when the heart muscle doesn’t get as much blood as it needs.

Lupin is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-infective and NSAID space.

It is among the leaders in the Anti-TB segment and is the sixth largest generics pharmaceutical company by revenue.

It is also the 4th largest pharmaceutical player in the US by prescriptions.

For the financial year ended 31 March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively.